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Abstract
Limb-girdle muscular dystrophies (LGMD) are genetic disorders characterized by weakness of predominantly proximal 
limb and trunk muscles due to progressive loss of muscle tissue. Collagen VI-related muscular dystrophies usually display 
more generalized muscle involvement combined with contractures and/or hyperlaxity of distal finger joints. LGMD-like 
phenotype of collagenopathy has only rarely been described and as reported is usually of childhood onset. We identified a 
Finnish family with COL6A2-related LGMD with autosomal dominant inheritance and very late onset at 40–60 years of 
age. Since the mutation was previously unreported, the pathognomonic findings on muscle MRI were the decisive clue for 
the correct diagnosis.
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Introduction
Limb-girdle muscular dystrophies (LGMD) are genetic 
disorders characterized by progressive weakness and loss 
of muscle tissue predominantly affecting proximal limb 
muscles. The degeneration of muscles is detectable both on 
muscle MRI and biopsy, which results in end-stage pathol-
ogy in the severely affected muscles. LGMDs are further 
subdivided into autosomal dominant and autosomal reces-
sive forms. The growing number and increasing hetero-
geneity of different LGMD forms reported over the years 
prompted a recent European Neuromuscular Center (ENMC) 
workshop to suggest revisions for the definition and clas-
sification of LGMD [1].
Muscle collagenopathies are caused by mutations in 
COL6A1, COL6A2 or COL6A3 genes, which encode differ-
ent alpha-subunits of fibroblast-secreted collagen VI fibrils 
deposited in the extracellular matrix. Collagen VI is required 
for the physical integrity and cohesion of muscle tissue as 
well as for signaling functions. The phenotype of collagen-
opathies usually includes a combination of contractures 
with progressive muscle weakness and wasting of variable 
severity [2]. An LGMD-like phenotype without significant 
contractures has been reported only rarely [3].
We describe a Finnish family with COL6A2-related domi-
nant LGMD and very late onset (40–60 years). An unre-
ported, unique mutation in the COL6A2 gene (c.2107A>C 
p.T703P, according to the transcript NM_001849) was 
identified in the proband using our targeted next-generation 
sequencing assay of myopathy-associated genes (MyoCap) 
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[4]. Sanger sequencing confirmed correct segregation of the 
detected mutation in three other family members.
Materials and methods
Patients
Four members of a Finnish family with late-onset, autoso-
mal dominant myopathy underwent clinical and laboratory, 
muscle imaging, histopathological and molecular genetics 
studies to identify the causative genetic defect. All patients 
provided informed consent for the examinations and the 
study was approved by the Tampere University Hospital 
ethics board.
DNA sequencing
DNA samples of the proband (II-2) and one of his affected 
sister’s (II-1) were studied by targeted next-generation 
sequencing. The exons of 363 myopathy-associated genes 
were targeted using our custom MYOcap assay (Roche 
Nimblegen, Madison, WI, USA). The list of targeted genes 
is available upon request. Nimblegen SeqCap EZ Choice 
Library protocol was used for capture and target enrichment. 
The enriched library was sequenced by Illumina HiSeq4000 
Sequencher to 75 bp paired-end read length. The capture, 
enrichment and next-generation sequencing were performed 
at Oxford Genomics Centre (OGC at Wellcome Trust Centre 
for Human Genetics, Oxford, UK). The read/raw data were 
analyzed using an in-house developed pipeline [4].
Sanger sequencing of exon 26 of COL6A2 gene was used 
to analyze DNA samples of family members II-3 and II-4. 
The exon of interest was amplified by PCR (2× PCR Mas-
ter Mix; ThermoFisher Scientific, Waltham, MA, USA) 
and sequenced using Big-Dye Terminator v3.1 Kit on an 
ABI3130×l automatic Genetic Analyzer (Applied Biosys-
tems, Foster City, CA, USA). Primer sequences are avail-
able upon request. Sequence analysis was performed with 
Sequencher 5.1 software (Gene Codes Corporation, Ann 
Arbor, MI).
Muscle MRI
MRI scans with axial sections of the lower limb muscles 
and using T1-weighted and short TI inversion recovery 
sequences were evaluated in four family members (II-1, 
II-2, II-3, II-4).
Muscle histopathology and immunofluorescence 
studies
Muscle biopsies were analyzed in patients II-1, II-2 and II-4, 
including hematoxylin and eosin (H&E), Gomöri trichrome, 
NADH-TR, COX-SDH and neonatal myosin heavy chain 
(MyHC) stains. MyHC slow and MyHC fast double stain-
ing was also assessed. For the immunofluorescence studies, 
the primary antibodies used for immunofluorescent double 
staining were mouse monoclonal anti-collagen VI, clone 
VI-26 (Merck MAB3303) and rat monoclonal anti-merosin/
LAMA2, clone 4H8-2 (Abcam ab11576). Muscle biopsies 
[patients II-1 and II-2; healthy control free of muscle dis-
ease; and disease control, a patient with early-onset collagen-
opathy (COL6A1 c.1056+1G>A p.G335_D352del)] were 
snap-frozen in liquid nitrogen-cooled isopentane, and 6 µm 
muscle cryosections were prepared on SuperFrost + sides. 
The sections were fixed with 4% PFA for 15 min, and per-
meabilized using 0.05% Triton X-100 in PBS for 10 min. 
After blocking with 2% BSA for 30 min, the pooled primary 
antibody mix was added and incubated at + 8 °C overnight. 
The following day, the slides were washed with PBS, and 
secondary antibody incubation was performed using Alexa-
546 and Alexa-488 conjugated antibodies, for 1 h at room 
temperature. An Axioplan 2 epifluorescence microscope 
(Carl Zeiss Microscopy GmbH) was used for imaging.
Results
The proband (II-2) first noticed proximal weakness in the 
lower limbs when lifting heavy objects or walking up stairs 
at the age of 59–60 years. Previously he had been athletic 
and in his forties he was still able to ski for 10 km. After age 
62, he had also experienced weakness in proximal upper 
limbs. On examination at age 66, he had proximal weak-
ness in the upper and lower limbs of MRC grade 3–4, slight 
scapular winging and distal weakness in the lower limbs 
(Table 1). EMG/NCS and muscle biopsy (Fig. 1, Table 1) 
showed abnormalities compatible with dystrophy, but also 
signs of neurogenic involvement most likely related to previ-
ous L4 radiculopathies. 
His two sisters (II-1, II-3) also had a similar phenotype 
characterized by proximal muscle weakness from ages 40 
and 50 years onwards, respectively. Lower limb muscle MRI 
showed layers of fatty replacement in a “tigroid” pattern 
(Fig. 2a, c and e). Muscle biopsies showed myopathic fea-
tures including fiber atrophy, increased internal nuclei and 
mild fibrofatty tissue replacement (Table 1, Fig. 1). None 
of the patients had significant joint contractures, although 
range of motion in ankle dorsiflexion was limited due to 
mildly tight heel cords.
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The patients were confirmed to carry a heterozy-
gous c.2107A>C p.T703P mutation in the COL6A2 gene 
(pedigree in Fig. 1). Targeted next-generation sequenc-
ing specified seven rare variants (MAF < 0.01) shared 
between proband and his affected sister II-1. Of these, only 
c.2107A>C in COL6A2 gene was unique and, therefore, 
considered likely pathogenic. This was supported by in 
silico pathogenicity prediction programs (Polyphen, Sift, 
Provean, Mutation Taster), which all predicted the vari-
ant to be damaging. Missense or synonymous variants in 
OBSCN, PLEC, PLEKHG4, NEB, ITGA7 were excluded on 
the basis that they were too common (MAF > 0.001) for a 
fully penetrant dominant mutation and because they were 
classified as benign/tolerated using in silico pathogenicity 
assessment tools. Furthermore, one of the variants was in a 
gene that is not expressed in skeletal muscle (MYLK3).The 
same COL6A2 mutation was detected by Sanger sequencing 
also in the affected sister II-3. One of the sisters (II-4) had 
minor myalgic complaints at age 60 years and was, therefore, 
also studied by muscle MRI, which showed normal findings 
(Fig. 2). She was found not to carry the COL6A2 variant that 
was detected in the affected family members.
We did not observe clear abnormality in the immunofluo-
rescent double staining of COLVI and merosin/LAMA2 in 
the muscle biopsies from patients II-1 and II-2, indicating 
that there is at least partial co-localization of these proteins, 
visualized as mostly yellow overlapping labeling in the mus-
cle fiber basal lamina (Fig. 3c, d).
Discussion
We describe a family with three patients having an LGMD-
like phenotype of collagenopathy with atypical late onset. 
Symptoms in Bethlem myopathy (OMIM #158,810) usually 
start in childhood with the majority of patients requiring 
mobility aids after 50 years of age [5].
Although distal lower limb weakness was present at the 
later disease stages in our patients, the initial symptoms in 
all our patients were due to proximal muscle weakness. A 
unique variant in COL6A2 (c. 2107 A>C p.T703P) was 
Fig. 1  a Pedigree of the family. Solid black symbols represent clini-
cally affected individuals. Individual I-2 labeled solid gray has not 
been clinically evaluated but was reportedly affected. DNA sample 
was available from individuals marked with a dot. b–d Pathological 
changes observed in tibialis anterior muscle biopsies (Haematoxylin 
andEosin stain). Muscle biopsy from the proband (II-2) shows dys-
trophic features including many internalized nuclei, fiber size vari-
ation, fiber splitting and increase of connective and adipose tissue. 
Small group atrophy signifying neurogenic involvement is also pre-
sent, probably related to an additional radiculopathy in this patient. 
Biopsies obtained from the proband’s sisters (II-1, II-3; c, d, respec-
tively) showed fiber atrophy, internal nuclei and endomysial fibrofatty 
degeneration
▸
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found to fully segregate with the phenotype in this family. 
Pathogenicity of the mutation is supported by the unusual 
and highly characteristic muscle MRI pattern, which is 
almost exclusively seen in collagenopathies [2], although it 
has also been rarely reported in calpainopathy [6]. Double 
immunofluorescence of collagen VI and merosin did not 
show obvious abnormalities, which is in line with previous 
reports in milder dominantly inherited collagenopathies, 
such as Bethlem myopathy. The double staining IF method 
is more useful in severe collagenopathy, where COL VI is 
Fig. 2  Lower limb magnetic resonance imaging shows characteristic 
fatty degeneration in the center of the rectus femoris and a layered, 
"tigroid" pattern in the vastus lateralis of patients II-1 (a), II-2 (c), 
II-3 (e), while thigh MRI was normal in the unaffected sibling II-4 (g) 
at 60 years of age. There is severe fatty replacement of the gastrocne-
mius medialis in all patients (b, d, f)
Fig. 3  Double staining using 
collagen VI (red) and merosin/
LAMA2 (green) antibodies in 
the normal control muscle (a) 
shows co-localization of the 
two labels, visualized as yellow 
labeling on the muscle fiber 
basal lamina. In a patient with 
early-onset severe collagen-
opathy (COL6A1), collagen 
(red) is largely detached from 
the basal lamina, resulting in 
green merosin labeling (b). The 
staining pattern in the proband’s 
II-2 (c) and his sister’s II-1 (d) 
muscle biopsies is not clearly 
abnormal, even though the 
interstitial space is enlarged 
showing collagen expression
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clearly detached from the myocyte basal lamina, and the co-
localization of COL VI and merosin is lost [2].
Collagen VI-related disorders are autosomal dominant 
or recessive disorders with phenotypes ranging from severe 
congenital muscular dystrophy to milder, adult-onset forms 
and are usually accompanied by variable degrees of joint 
contractures [2]. Our patients did not have contractures or 
spinal deformities, although some degree of Achilles tendon 
tightness was present in all. However, this is a nonspecific 
finding and not very significant considering the age of the 
patients.
LGMD-type of collagenopathy without contractures has 
been reported only rarely and according to the new ENMC 
classification, would be labeled as LGMD D5 (dominant) or 
LGMD R22 (recessive). The family reported here meets the 
criteria for a late-onset form of LGMD D5, caused by the 
COL6A2 mutation c. 2107 A>C p.T703P.
Although sporadic inclusion body myositis is the most 
common muscle disease in patients over 50 years of age, 
it is important to recognize that several genetic myopa-
thies and dystrophies may also manifest at this age. Indeed, 
some of the most common LGMD forms in Finland, such 
as LGMD2L (anoctaminopathy) and DNAJB6-related 
LGMD1D, frequently become symptomatic only after 50 
years of age [7]. Accurate family history may be especially 
difficult to obtain in these very late-onset patients, because 
of the many other age-related neuromuscular complaints in 
this age group. Similarly, the proband (II-2) of our family 
had signs of neurogenic disease in the lower limbs both on 
EMG and muscle biopsy, which might have been considered 
the cause of his symptoms, had the muscle MRI not been 
performed. Our study, therefore, shows that muscle MRI is 
a valuable tool to help sorting out different neuromuscular 
disorders also in elderly patients.
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